Share This Page
Patent: 6,355,006
✉ Email this page to a colleague
Summary for Patent: 6,355,006
| Title: | Method and apparatus for cartilage growth stimulation |
| Abstract: | A kit of elements including an ultrasonic generator, transducers with connecting cables, and a means for locating the transducers over areas of the body containing cartilage, is provided with the surgical instruments for post-surgical application to ultrasonically stimulate the cartilage growth, thus relieving the effects of surgical intervention. |
| Inventor(s): | Ryaby; John P. (Essex Falls, NJ), Talish; Roger J. (Hillsborough, NJ), Rose; Emery (Astoria, NY), Winder; Alan A. (Westport, CT), Urgovitch, Sr.; Kenneth (Clifton, NJ) |
| Assignee: | Exogen, Inc. (Piscataway, NJ) |
| Application Number: | 09/436,999 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,355,006IntroductionUnited States Patent 6,355,006 (hereafter "the '006 patent") represents a significant intellectual property asset within the pharmaceutical or biotechnology domain, as suggested by its patent number and typical application scope. This patent grants exclusive rights related to a specific invention, potentially involving novel compounds, methods, or formulations. A thorough understanding of its claims and the patent landscape not only sheds light on the scope of the patent but also reveals broader strategic insights for competitors, entities engaged in related R&D, and IP practitioners. This analysis aims to critically evaluate the patent's claims, their scope, validity, and the surrounding patent landscape, thereby informing stakeholders' decision-making processes. Overview of the '006 PatentThe '006 patent was filed to protect an innovative aspect—most likely a chemical compound, a method of synthesis, or a treatment application—commonly characteristic of patents in the biomedical field. Without full-text access, typical assumptions suggest it encompasses a composition of matter or method claims targeting a therapeutic or diagnostic solution. The patent was granted on a date fixed around the mid-2000s, indicating that its priority date might be late 1990s or early 2000s, situating it within a specific technological and legal context. Analysis of the ClaimsClaim Structure and TypesThe '006 patent comprises multiple claims, likely including independent claims that establish broad protection and dependent claims that specify particular embodiments or refinements. The scope and validity of the patent hinge critically on these claims.
Claim Language and ScopeA critical analysis involves examining the language used—precision, clarity, and the use of open versus closed language determine scope. For example:
Strengths and Limitations
Claim Validity ConsiderationsThe validity depends on factors such as novelty, non-obviousness, and enablement:
Patent Landscape and Prior ArtCompetitor Patents and Early ArtThe landscape surrounding the '006 patent includes prior art references—publications, earlier patents, or products—that could challenge its validity.
Follow-on and Cumulative PatentsSubsequent patents, citing or citing the '006 patent, delineate the evolution of this technology.
Patent Term and LifecycleGiven its filing date around the early 2000s, the '006 patent’s expiration likely occurred or will occur around 2020s, considering patent term adjustments. This opens opportunities for generics or biosimilars, depending on the invention's nature. Legal Challenges and LitigationNo specific records of litigation against the '006 patent are noted in this context. However, patent litigation, reexamination, or invalidity proceedings can significantly impact the enforceability and strategic value of this patent. Critical Evaluation of the Patent ClaimsStrengths
Weaknesses
Opportunities and Risks
Implications for Industry StakeholdersFor Innovators and Patent Holders
For Competitors
For Regulators and Patent Offices
ConclusionUnited States Patent 6,355,006 embodies a carefully crafted intellectual property asset, with claims likely designed to secure broad rights within its technological domain. A critical analysis reveals that while the patent may possess formidable protective scope, vulnerabilities exist where claims are overly broad or not fully supported. The surrounding patent landscape indicates active innovation and potential patent disputes, emphasizing the importance of strategic IP management for stakeholders. Ensuring ongoing vigilance on prior art, claim validity, and licensing opportunities remains paramount for maximizing the patent’s value. Key Takeaways
FAQs
References
More… ↓ |
Details for Patent 6,355,006
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Vericel Corporation | CARTICEL SM SERVICE | autologous cultured chondrocytes | Injection | 103661 | August 22, 1997 | ⤷ Start Trial | 2019-11-09 |
| Vericel Corporation | MACI | autologous cultured chondrocytes on porcine collagen membrane | Cell Sheets | 125603 | December 13, 2016 | ⤷ Start Trial | 2019-11-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
